Most men who are treated for prostate cancer according to modern guidelines have good survival rates and the majority of these men will die of causes other than prostate cancer. This is revealed in a ...
Hosted on MSN
Prostate cancer patients could avoid overtreatment if NICE updated its guidelines, charity says
Up to 5,000 men a year could avoid potentially harmful treatment for prostate cancer if ‘outdated’ guidelines reflected the latest evidence, a charity has said. Closely monitoring the disease with ...
Prostate cancer is one of the leading causes of cancer-related death in men, and some experts project the number of cases to rise over the coming decades. But in a recent Urologic Oncology article, ...
Hosted on MSN
Study Finds Most Prostate Cancer Patients Following NCCN Guidelines Live Long, Healthy Lives
PLYMOUTH MEETING, PA — New research published in the July 2025 issue of JNCCN—Journal of the National Comprehensive Cancer Network offers encouraging news for men diagnosed with nonmetastatic prostate ...
People with localized prostate cancer treated according to guidelines developed by an international panel of doctors are more likely to die of something other than the disease, new research shows. A ...
SALT LAKE CITY, Dec. 09, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc (MYGN). (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced that its Prolaris prostate cancer ...
Patients with nonmetastatic prostate cancer are more likely to die from other causes than from cancer when treated per guidelines. The 15-year cancer mortality risk is 5.5% for low-risk and 22% for ...
About 70% of physicians said they were not following the recommended guidelines for the treatment of metastatic prostate cancer, according to a study published Dec. 9 in JAMA Network Open. Metastatic ...
Risk of death and cause of death 30 years after diagnosis as a proportion of 100 men. Grey figures indicate the proportion of men alive after 30 years, blue figures the proportion of men who died of ...
A growing array of pharmaceutical options has investigators trying to figure out which drugs and drug combinations are the best to prescribe upfront—and to which patients. Over the past 14 years, ...
To earn CME related to this news article, click here. February 25, 2009 — A new joint guideline produced by the American Society of Clinical Oncology (ASCO) and the American Urological Association ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results